Nuntius and Taiho Collaborate to Advance Cancer Medications

In an effort to create cutting-edge messenger ribonucleic acid (mRNA) cancer immunotherapies, Japan’s Taiho Pharmaceutical and the UK-based biotechnology business Nuntius Therapeutics have signed a strategic partnership arrangement.

Through this agreement, mRNA delivery will be significantly advanced since Nuntius’ nanocarrier technologies—which have the ability to target cell types other than the liver—will be utilised. Additionally, the partnership comes after a fruitful feasibility investigation showcasing the potential of Nuntius’ lipid- and cell-specific peptide dendrimer-based nanocarriers.

Nuntius Therapeutics CEO and co-founder Benita Nagel commented: “We are thrilled to embark on this collaboration with Taiho to improve treatments for cancer patients. Taiho is an excellent partner for us given their strong oncology-focused research and commercial capabilities.”

Nuntius combines cutting-edge nucleic acid engineering, machine learning, and proprietary delivery technology to develop novel mRNA treatments. The company is creating a pipeline of mRNA therapies for use in neurological disorders, pulmonary conditions, and cancer.